BIOMARKER:

KRAS G12C

News alerts, weekly reports and conference planners

Entrez ID:

3845

Related biomarkers:

‹

›

KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New B) sotorasib Sensitive : A1 ESMO 2022 - 3wk	sotorasib Sensitive: A1 - Approval ESMO 2022 - 3 weeks sotorasib Sensitive : A1 ESMO 2022 - 3 weeks - (New B)
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	MRTX849 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) MRTX849 Sensitive : C2 ESMO 2022 - 3wk	MRTX849 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks MRTX849 Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	RG6330 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) RG6330 Sensitive : C2 ESMO 2022 - 3wk	RG6330 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks RG6330 Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	RG6330 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) RG6330 Sensitive : C2 ESMO 2022 - 3wk	RG6330 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks RG6330 Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	cetuximab + MRTX849 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) cetuximab + MRTX849 Sensitive : C3 ESMO 2022 - 3wk	cetuximab + MRTX849 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks cetuximab + MRTX849 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	panitumumab + sotorasib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) panitumumab + sotorasib Sensitive : C3 ESMO 2022 - 3wk	panitumumab + sotorasib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks panitumumab + sotorasib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	bevacizumab Resistant: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) bevacizumab Resistant : C3 ESMO 2022 - 3wk	bevacizumab Resistant: C3 – Early Trials ESMO 2022 - 3 weeks bevacizumab Resistant : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab + rigosertib Sensitive : C3 ESMO 2022 - 3wk	nivolumab + rigosertib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab + rigosertib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	MRTX849 Sensitive: B - Late Trials MRTX849 Sensitive : B	MRTX849 Sensitive: B - Late Trials MRTX849 Sensitive : B
KRAS G12C	Lung Non-Squamous Non-Small Cell Cancer	KRAS G12C	Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	cetuximab Resistant: B - Late Trials cetuximab Resistant : B	cetuximab Resistant: B - Late Trials cetuximab Resistant : B
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	panitumumab Resistant: B - Late Trials panitumumab Resistant : B	panitumumab Resistant: B - Late Trials panitumumab Resistant : B
KRAS G12C	Ampulla of Vater Carcinoma	KRAS G12C	Ampulla of Vater Carcinoma	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Pancreatic Cancer	KRAS G12C	Pancreatic Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Melanoma	KRAS G12C	Melanoma	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Endometrial Cancer	KRAS G12C	Endometrial Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Gastrointestinal Cancer	KRAS G12C	Gastrointestinal Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	D-1553 Sensitive: C2 – Inclusion Criteria D-1553 Sensitive : C2	D-1553 Sensitive: C2 – Inclusion Criteria D-1553 Sensitive : C2
KRAS G12C	Lung Cancer	KRAS G12C	Lung Cancer	D-1553 Sensitive: C2 – Inclusion Criteria D-1553 Sensitive : C2	D-1553 Sensitive: C2 – Inclusion Criteria D-1553 Sensitive : C2
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	MEK inhibitor + sotorasib Sensitive: C2 – Inclusion Criteria MEK inhibitor + sotorasib Sensitive : C2	MEK inhibitor + sotorasib Sensitive: C2 – Inclusion Criteria MEK inhibitor + sotorasib Sensitive : C2
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	SAR442720 Sensitive: C2 – Inclusion Criteria SAR442720 Sensitive : C2	SAR442720 Sensitive: C2 – Inclusion Criteria SAR442720 Sensitive : C2
KRAS G12C	Gastrointestinal Cancer	KRAS G12C	Gastrointestinal Cancer	MRTX849 Sensitive: C2 – Inclusion Criteria MRTX849 Sensitive : C2	MRTX849 Sensitive: C2 – Inclusion Criteria MRTX849 Sensitive : C2
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	GFH925 Sensitive: C2 – Inclusion Criteria GFH925 Sensitive : C2	GFH925 Sensitive: C2 – Inclusion Criteria GFH925 Sensitive : C2
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	JAB-21822 Sensitive: C2 – Inclusion Criteria JAB-21822 Sensitive : C2	JAB-21822 Sensitive: C2 – Inclusion Criteria JAB-21822 Sensitive : C2
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	D-1553 Sensitive: C2 – Inclusion Criteria D-1553 Sensitive : C2	D-1553 Sensitive: C2 – Inclusion Criteria D-1553 Sensitive : C2
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	RG6330 Sensitive: C2 – Inclusion Criteria RG6330 Sensitive : C2	RG6330 Sensitive: C2 – Inclusion Criteria RG6330 Sensitive : C2
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3
KRAS G12C	Cholangiocarcinoma	KRAS G12C	Cholangiocarcinoma	MRTX849 Sensitive: C3 – Early Trials MRTX849 Sensitive : C3	MRTX849 Sensitive: C3 – Early Trials MRTX849 Sensitive : C3
KRAS G12C	Ovarian Cancer	KRAS G12C	Ovarian Cancer	MRTX849 Sensitive: C3 – Early Trials MRTX849 Sensitive : C3	MRTX849 Sensitive: C3 – Early Trials MRTX849 Sensitive : C3
KRAS G12C	Pancreatic Cancer	KRAS G12C	Pancreatic Cancer	MRTX849 Sensitive: C3 – Early Trials MRTX849 Sensitive : C3	MRTX849 Sensitive: C3 – Early Trials MRTX849 Sensitive : C3
KRAS G12C	Endometrial Cancer	KRAS G12C	Endometrial Cancer	MRTX849 Sensitive: C3 – Early Trials MRTX849 Sensitive : C3	MRTX849 Sensitive: C3 – Early Trials MRTX849 Sensitive : C3
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	IN10018 + MRTX1257 Sensitive: C3 – Early Trials IN10018 + MRTX1257 Sensitive : C3	IN10018 + MRTX1257 Sensitive: C3 – Early Trials IN10018 + MRTX1257 Sensitive : C3
KRAS G12C	Hepatocellular Cancer	KRAS G12C	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3

KRAS G12C

Associations